Clinical Trials Logo

Clinical Trial Summary

The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01986270
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date December 1996
Completion date January 1998

See also
  Status Clinical Trial Phase
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Completed NCT00383162 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Phase 3
Completed NCT01986088 - Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Phase 3
Completed NCT02605174 - Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine Phase 3
Completed NCT01978496 - Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine Phase 3
Completed NCT01989936 - Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Phase 3
Completed NCT03061734 - Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine Phase 2
Completed NCT06245902 - An Acute Migraine Factorial Study Phase 2
Completed NCT00382993 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Phase 3
Completed NCT03194555 - The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination Phase 2